Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
AHA 2017
Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
- David H. Birnie, MD
A coordinated effort to organise STEMI care improved treatment time and patient outcomes
A coordinated effort to organise STEMI care improved treatment time and patient outcomes
AHA 2017
A coordinated effort to organise STEMI care improved treatment time and patient outcomes
- James Jollis, MD
Sodium Bicarbonate and N-Acetylcysteine tested for the prevention of serious adverse outcomes
Sodium Bicarbonate and N-Acetylcysteine tested for the prevention of serious adverse outcomes
AHA 2017
Sodium Bicarbonate and N-Acetylcysteine tested for the prevention of serious adverse outcomes
More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses
More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses
AHA 2017
More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses